Roth Capital raised the firm’s price target on Stryker (SYK) to $456 from $405 and keeps a Buy rating on the shares. The company’s Q1 earnings quality was good with strong gross margins, while the management’s stronger organic sales outlook, operating leverage, and better than expected FX easily offset an expected $200M impact from tariffs in 2025, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker’s Strong Financial Performance and Strategic Initiatives Drive Buy Rating
- Stryker’s Strong Q1 2025 Performance and Resilience Justify Buy Rating Despite Tariff Challenges
- Stryker Corp Reports Strong Q1 2024 Earnings Growth
- Closing Bell Movers: Apple and Amazon slip after earnings
- Stryker sees FY25 adjusted EPS $13.20-$13.45, consensus $13.45